Simulations Plus (NASDAQ:SLP) Announces Earnings Results

Simulations Plus (NASDAQ:SLP) posted its earnings results on Thursday. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.06, Zacks reports. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%.

Simulations Plus Stock Down 3.8 %

Shares of Simulations Plus stock traded down $0.95 during trading on Thursday, reaching $23.82. 329,975 shares of the stock were exchanged, compared to its average volume of 175,213. The firm has a market cap of $478.59 million, a price-to-earnings ratio of 59.55 and a beta of 0.89. Simulations Plus has a 1 year low of $23.00 and a 1 year high of $51.22. The stock’s fifty day moving average is $30.38 and its 200 day moving average is $30.38.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on SLP. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp raised their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Simulations Plus presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.